Article Text
Short report
Growth hormone and respiratory compromise in Prader–Willi Syndrome
Abstract
Recombinant human growth hormone (rhGH) therapy in Prader–Willi syndrome (PWS) causes increased basal metabolic rate and oxygen consumption, and hence increased ventilatory load. The case of an adolescent with PWS who experienced respiratory deterioration with an increase in rhGH and improvement with cessation of therapy is reported.
- growth hormone
- Prader-Willi syndrome
- sleep apnoea syndrome
- respiratory insufficiency
- basal metabolism